None of those cases are similar to the Momenta vs. Teva case and I certainly don't think that Momenta's IP is worthless, rather I wanted to show how the courts increasingly have expanded the scope of the safe harbor provision. Patented research tools may well fall outside the safe harbor exemption.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.